Sienna Biopharmaceuticals, Inc.
SNNA
SNNA was delisted on the 16th of December, 2019.
53 hedge funds and large institutions have $151M invested in Sienna Biopharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 27 increasing their positions, 10 reducing their positions, and 7 closing their positions.
170% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 10
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
2% more funds holding
Funds holding: 52 → 53 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
18% less capital invested
Capital invested by funds: $184M → $151M (-$33M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.75M |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
+$3.06M |
| 3 |
Morgan Stanley
New York
|
+$1.82M |
| 4 |
AG
Artal Group
Luxembourg
|
+$1.68M |
| 5 |
BlackRock
New York
|
+$1.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TimesSquare Capital Management
New York
|
-$6.76M |
| 2 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$6.02M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$751K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$386K |
| 5 |
CAG
Crestwood Advisors Group
Boston,
Massachusetts
|
-$233K |
SNNA Hedge Fund Activity: Q2 2018 in Review
53 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Sienna Biopharmaceuticals, Inc. (SNNA) for Q2 2018, worth a combined $151M — down 18% from $184M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SNNA positions and 7 closed out — a net gain of 1 holder — while 27 added to existing stakes and 10 trimmed.
The largest buyer was Vanguard Group, adding an estimated $3.75M. The largest seller was TimesSquare Capital Management, exiting entirely with an estimated $6.76M sold.
- 53 institutional investors held Sienna Biopharmaceuticals, Inc. (SNNA) as of Q2 2018, up from 52 in Q1 2018.
- Funds reported $151M of Sienna Biopharmaceuticals, Inc. stock for Q2 2018, down 18% quarter-over-quarter.
- 8 funds opened new Sienna Biopharmaceuticals, Inc. positions in Q2 2018 and 7 closed out, a net change of +1 holder.
- The largest Sienna Biopharmaceuticals, Inc. buyer in Q2 2018 was Vanguard Group, an estimated $3.75M added.
- The largest Sienna Biopharmaceuticals, Inc. seller in Q2 2018 was TimesSquare Capital Management, an estimated $6.76M sold.
Based on aggregated 13F filings for Q2 2018.